BioCentury | Nov 4, 2013
Clinical News

Antara fenofibrate regulatory update

...Oscient Pharmaceuticals Corp. , which has been dissolved. Oscient had U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Strategy

Vivus' weighting game

...build more than a product launch," he added. A successful market build, Miller noted, was Reliant Pharmaceuticals Inc....
BioCentury | Jan 23, 2012
Finance

M&A bounty for VCs

...in 2007 was primarily due to the inclusion of the $1.7 billion takeout of venture-backed Reliant Pharmaceuticals Inc....
BioCentury | Feb 7, 2011
Company News

Amarin management update

...NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Hired: Paul Huff as CCO, formerly VP of marketing at Reliant Pharmaceuticals Inc. WIR...
BioCentury | May 27, 2010
Targets & Mechanisms

The case against triglycerides

...increased triglycerides. Pronova Biopharma ASA licensed the U.S. rights to the fish oil formulation to Reliant Pharmaceuticals...
BioCentury | Oct 19, 2009
Finance

Ebb & Flow

...Lovaza eicosapentaenoic acid/docosanexaenoic acid. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which obtained Lovaza through its acquisition of Reliant Pharmaceuticals Inc....
BioCentury | Jul 20, 2009
Company News

Cornerstone Therapeutics, Oscient deal

...a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Jun 22, 2009
Company News

Oscient infectious, metabolic news

...Oscient has U.S. rights to Antara, a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia, from Reliant Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

Oscient infectious, metabolic news

...and a nine-month operating loss of $29.5 million. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Jan 19, 2009
Company News

Ethypharm, Oscient, Lupin metabolic news

...FDA for a generic version of fenofibrate. Oscient acquired U.S. marketing rights to Antara from Reliant Pharmaceuticals Inc....
Items per page:
1 - 10 of 64
BioCentury | Nov 4, 2013
Clinical News

Antara fenofibrate regulatory update

...Oscient Pharmaceuticals Corp. , which has been dissolved. Oscient had U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Strategy

Vivus' weighting game

...build more than a product launch," he added. A successful market build, Miller noted, was Reliant Pharmaceuticals Inc....
BioCentury | Jan 23, 2012
Finance

M&A bounty for VCs

...in 2007 was primarily due to the inclusion of the $1.7 billion takeout of venture-backed Reliant Pharmaceuticals Inc....
BioCentury | Feb 7, 2011
Company News

Amarin management update

...NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Hired: Paul Huff as CCO, formerly VP of marketing at Reliant Pharmaceuticals Inc. WIR...
BioCentury | May 27, 2010
Targets & Mechanisms

The case against triglycerides

...increased triglycerides. Pronova Biopharma ASA licensed the U.S. rights to the fish oil formulation to Reliant Pharmaceuticals...
BioCentury | Oct 19, 2009
Finance

Ebb & Flow

...Lovaza eicosapentaenoic acid/docosanexaenoic acid. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which obtained Lovaza through its acquisition of Reliant Pharmaceuticals Inc....
BioCentury | Jul 20, 2009
Company News

Cornerstone Therapeutics, Oscient deal

...a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Jun 22, 2009
Company News

Oscient infectious, metabolic news

...Oscient has U.S. rights to Antara, a lipid-lowering agent to treat hypercholesterolemia and hypertriglyceridemia, from Reliant Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

Oscient infectious, metabolic news

...and a nine-month operating loss of $29.5 million. Oscient has U.S. rights to Antara from Reliant Pharmaceuticals Inc....
BioCentury | Jan 19, 2009
Company News

Ethypharm, Oscient, Lupin metabolic news

...FDA for a generic version of fenofibrate. Oscient acquired U.S. marketing rights to Antara from Reliant Pharmaceuticals Inc....
Items per page:
1 - 10 of 64